Dillon & Associates Inc. Sells 145 Shares of Merck & Co., Inc. (NYSE:MRK)

Dillon & Associates Inc. reduced its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 4.0% in the fourth quarter, HoldingsChannel reports. The firm owned 3,451 shares of the company’s stock after selling 145 shares during the quarter. Dillon & Associates Inc.’s holdings in Merck & Co., Inc. were worth $376,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in MRK. Allworth Financial LP increased its holdings in Merck & Co., Inc. by 5.7% in the 3rd quarter. Allworth Financial LP now owns 43,711 shares of the company’s stock worth $4,500,000 after acquiring an additional 2,351 shares in the last quarter. Centerpoint Advisors LLC increased its holdings in Merck & Co., Inc. by 3.7% in the 3rd quarter. Centerpoint Advisors LLC now owns 2,808 shares of the company’s stock worth $289,000 after acquiring an additional 100 shares in the last quarter. New Mexico Educational Retirement Board increased its holdings in Merck & Co., Inc. by 7.1% in the 3rd quarter. New Mexico Educational Retirement Board now owns 131,986 shares of the company’s stock worth $13,588,000 after acquiring an additional 8,800 shares in the last quarter. Verus Capital Partners LLC increased its holdings in Merck & Co., Inc. by 26.5% in the 3rd quarter. Verus Capital Partners LLC now owns 5,866 shares of the company’s stock worth $604,000 after acquiring an additional 1,228 shares in the last quarter. Finally, Congress Asset Management Co. MA increased its holdings in Merck & Co., Inc. by 1.5% in the 3rd quarter. Congress Asset Management Co. MA now owns 144,226 shares of the company’s stock worth $14,848,000 after acquiring an additional 2,077 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Truist Financial increased their target price on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Barclays upped their price target on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. UBS Group upped their price target on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Finally, Wells Fargo & Company upped their price target on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $131.33.

Get Our Latest Research Report on MRK

Merck & Co., Inc. Price Performance

Shares of NYSE MRK traded up $0.31 during midday trading on Friday, reaching $131.19. 8,281,595 shares of the stock traded hands, compared to its average volume of 7,287,899. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The stock has a market capitalization of $332.28 billion, a PE ratio of 145.77, a P/E/G ratio of 1.67 and a beta of 0.39. Merck & Co., Inc. has a one year low of $99.14 and a one year high of $133.10. The company’s 50 day moving average is $127.27 and its 200 day moving average is $118.62.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. Merck & Co., Inc.’s revenue was up 8.9% on a year-over-year basis. During the same period last year, the company earned $1.40 earnings per share. On average, equities research analysts anticipate that Merck & Co., Inc. will post 8.69 earnings per share for the current year.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.